Poly Medicure Ltd reported a 25.5% year-on-year increase in consolidated net profit to ₹93.1 crore for the first quarter of FY26, while total income grew 10.7% to ₹444.9 crore.
| Metric | Q1 FY26 | Q1 FY25 | YoY Growth (%) |
|---|---|---|---|
| Total Income | 444.9 | 401.7 | 10.7% |
| Gross Profit | 276.0 | 256.5 | 7.6% |
| Gross Profit Margin | 68.4% | 66.7% | 170BPS |
| Operating EBITDA | 106.1 | 103.8 | 2.1% |
| Operating EBITDA Margin | 26.3% | 27.0% | -70BPS |
| Profit after Tax | 93.1 | 74.0 | 25.5% |
| PAT Margin | 20.9% | 18.4% | 250BPS |
| EPS - Basic | 9.2 | 7.7 | 18.8% |
Key Business Highlights:
Total Income grew by 10.7% in Q1 FY26 as compared to Q1 FY25, supported by strong Domestic performance.
Domestic operating revenue grew by 20.1% on a YoY basis, reflecting sustained traction in domestic market.
Revenue from international market, which contributes approximately 70% of consolidated revenue, declined by 0.9%, impacted by short-term demand uncertainties due to on-going geopolitical tensions and tariff related headwinds
Operating EBITDA margin stood at 26.3%.
Profit After Tax (PAT) increased by 25.5% in Q1 FY26 compared to Q1 FY25; PAT margin expanded by almost 250bps to 20.9% in Q1 FY26.
The company maintains a zero net debt position, with adequate liquidity of ₹1,248.6 Crore as of June 30, 2025.
Incurred a CAPEX of ₹95 Crore in Q1 FY26 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector.
Commenting on the results for the quarter, Mr. Himanshu Baid, Managing Director, Poly Medicure Limited stated:
We are pleased to share that we started the year on a steady note, with our Domestic revenue continuing to demonstrate strong growth momentum. This is supported by a healthy operating margin, enhanced PAT performance and significant product innovations-all while continuing to invest in sustainability, scale, and future capacity through R&D and green initiatives.
Our renal division continues to grow at a robust pace, and with the commercialization of our Critical Care and Cardiology division last year, we are further expanding our presence in the larger Medical Devices industry.
While short term challenges persist due to geopolitical tensions and recent tariff changes, we remain confident about the long term opportunity in for the Indian Medical Devices sector and continue to position ourselves strongly to capture that. We remain steadfast to our vision of "Serving people through innovative healthcare solutions".
Poly Medicure Ltd is a leading medical device manufacturer and exporter from India, with its products sold in over 125+ countries, making a significant global impact on healthcare. With a robust portfolio of over 200+ medical devices and more than 300+ patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management. Supported by 12 state-of-the-art manufacturing facilities across 4 countries, Polymed has the capacity to produce over 1.8 billion medical devices annually, meeting the ever-growing global demand. The company's diverse product offering ensures it addresses a wide range of medical needs worldwide.
Hitesh Sardana, Corporate Communication hitesh.sardana@polymedicure.com
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
